Bavarian Nordic, J&J infectious news
The EU’s Innovative Medicines Initiative (IMI) awarded over ÿ100 million ($118.2 million) to consortia supporting the development, manufacturing and patient education for Johnson & Johnson’s Ad26-MVA combination Ebola vaccine regimen. J&J said the grant agreements are still being finalized and information on budget details will be published once signed.
The vaccine regimen was developed under a collaboration between J&J’s Crucell N.V. subsidiary and Bavarian Nordic. The prime-boost Ebola virus vaccine comprises two vaccine components based on Crucell’s AdVac technology and Bavarian Nordic’s MVA-BN technology. Earlier this month, the Oxford Vaccine Group of the University of Oxford (Oxford, U.K.) began a U.K. Phase I trial to evaluate the Ad26-MVA Ebola vaccine regimen. In October, Bavarian Nordic granted Crucell exclusive, worldwide rights to MVA-BN Filo, a modified vaccinia Ankara (MVA) multivalent vaccine (see BioCentury, Oct. 27, 2014) ...